These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 30122369)
21. Design, synthesis, structure-activity relationships and X-ray structural studies of novel 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as selective and potent inhibitors of human aldose reductase. Crespo I; Giménez-Dejoz J; Porté S; Cousido-Siah A; Mitschler A; Podjarny A; Pratsinis H; Kletsas D; Parés X; Ruiz FX; Metwally K; Farrés J Eur J Med Chem; 2018 May; 152():160-174. PubMed ID: 29705708 [TBL] [Abstract][Full Text] [Related]
22. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites. El-Kabbani O; Podjarny A Cell Mol Life Sci; 2007 Aug; 64(15):1970-8. PubMed ID: 17497245 [TBL] [Abstract][Full Text] [Related]
23. On-bead combinatorial techniques for the identification of selective aldose reductase inhibitors. Robins LI; Dixon SM; Wilson DK; Kurth MJ Bioorg Med Chem; 2006 Dec; 14(23):7728-35. PubMed ID: 16931029 [TBL] [Abstract][Full Text] [Related]
24. Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. Van Zandt MC; Doan B; Sawicki DR; Sredy J; Podjarny AD Bioorg Med Chem Lett; 2009 Apr; 19(7):2006-8. PubMed ID: 19250825 [TBL] [Abstract][Full Text] [Related]
25. Pterin-7-carboxamides as a new class of aldose reductase inhibitors. Saito R; Suzuki S; Sasaki K Bioorg Med Chem Lett; 2016 Oct; 26(20):4870-4874. PubMed ID: 27666634 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of aldose reductase inhibition and docking studies of 6'-nitro and 6',6''-dinitrorosmarinic acids. Koukoulitsa C; Bailly F; Pegklidou K; Demopoulos VJ; Cotelle P Eur J Med Chem; 2010 Apr; 45(4):1663-6. PubMed ID: 20071057 [TBL] [Abstract][Full Text] [Related]
27. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Giannoukakis N Expert Opin Investig Drugs; 2008 Apr; 17(4):575-81. PubMed ID: 18363521 [TBL] [Abstract][Full Text] [Related]
28. Substituted derivatives of indole acetic acid as aldose reductase inhibitors with antioxidant activity: structure-activity relationship. Juskova M; Majekova M; Demopoulos V; Stefek M Gen Physiol Biophys; 2011 Dec; 30(4):342-9. PubMed ID: 22131315 [TBL] [Abstract][Full Text] [Related]
29. N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase. Nencetti S; La Motta C; Rossello A; Sartini S; Nuti E; Ciccone L; Orlandini E Bioorg Med Chem; 2017 Jun; 25(12):3068-3076. PubMed ID: 28392277 [TBL] [Abstract][Full Text] [Related]
30. Identification of new potent inhibitor of aldose reductase from Ocimum basilicum. Bhatti HA; Tehseen Y; Maryam K; Uroos M; Siddiqui BS; Hameed A; Iqbal J Bioorg Chem; 2017 Dec; 75():62-70. PubMed ID: 28917123 [TBL] [Abstract][Full Text] [Related]
31. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives. Liu J; Wen G; Cao D Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700 [TBL] [Abstract][Full Text] [Related]
32. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and evaluation of rhodanine derivatives as aldose reductase inhibitors. Agrawal YP; Agrawal MY; Gupta AK Chem Biol Drug Des; 2015 Feb; 85(2):172-80. PubMed ID: 24903533 [TBL] [Abstract][Full Text] [Related]
34. Development of novel pyrazolone derivatives as inhibitors of aldose reductase: an eco-friendly one-pot synthesis, experimental screening and in silico analysis. Kadam A; Dawane B; Pawar M; Shegokar H; Patil K; Meshram R; Gacche R Bioorg Chem; 2014 Apr; 53():67-74. PubMed ID: 24607578 [TBL] [Abstract][Full Text] [Related]
35. CADD Studies in the Discovery of Potential ARI (Aldose Reductase Inhibitors) Agents for the Treatment of Diabetic Complications. Gupta SK; Tripathi PK Curr Diabetes Rev; 2023; 19(9):e180822207672. PubMed ID: 35993470 [TBL] [Abstract][Full Text] [Related]
36. The role of aldose reductase inhibitors in diabetic complications: recent trends. Kaul CL; Ramarao P Methods Find Exp Clin Pharmacol; 2001 Oct; 23(8):465-75. PubMed ID: 11838322 [TBL] [Abstract][Full Text] [Related]